Q-omics provides the consensus-scored KCTD9P3 profile across patient tissues and cancer cell-line models. KCTD9P3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, KCTD9P3 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, KCTD9P3 RNA expression shows 6,481 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, HNSC, and STAD as cancer lineages where KCTD9P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD9P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD9P3 survival associations across molecular data types. KCTD9P3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD9P3 RNA expression–survival associations across cancer types. High KCTD9P3 expression shows unfavorable associations in TGCT, UCEC, LGG, ACC and DLBC, but favorable associations in ESCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify TGCT as the clearest survival context for KCTD9P3 RNA expression.
This table summarizes KCTD9P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KCTD9P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD9P3 shows lower tumor expression in PAAD and higher tumor expression in HNSC and STAD. The HNSC box plot shows higher KCTD9P3 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .005).
This table shows molecular features associated with KCTD9P3 in patient tissues and cancer cell lines. In patient samples, KCTD9P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
